Rio de Janeiro State University

About: Rio de Janeiro State University is a education organization based out in Rio de Janeiro, Brazil. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 16631 authors who have published 30919 publications receiving 465753 citations. The organization is also known as: UERJ & Rio de Janeiro State University.

Tectonic evolution of the Brasília Belt, Central Brazil, and early assembly of Gondwana

Abstract: Abstract The Brasília Belt comprises terranes and thrust-sheets that were tectonically transported towards the western passive margin of the São Francisco–Congo palaeocontinent during an orogenic episode resulting from collision of the Paranapanema and Goiás blocks and the Goiás magmatic arc against São Francisco–Congo at 0.64–0.61 Ga. The tectonic zones of the belt are, from east to west: a foreland zone with Archaean–Palaeoproterozoic granite–greenstone basement covered by Neoproterozoic anchimetamorphic sedimentary rocks (Bambuí Group); a low metamorphic grade thrust-fold belt of proximal shelf successions, mostly siliciclastic, containing rare basement slivers; metamorphic nappes in upper greenschist to granulite facies of distal shelf and slope metasediments and subordinate tholeiitic metabasalts; the Goiás massif, possibly a microcontinent; and the Goiás magmatic arc. The accretion of these terranes against the western margin of the São Francisco–Congo palaeocontinent took place during an early phase of Gondwana supercontinent amalgamation, when terranes accreted around São Francisco–Congo to create a proto-West Gondwana landmass, around which subsequent collisional and accretionary events followed, such as those in the Borborema–Trans-Saharan province (c. 0.62–0.60 Ga); in the Ribeira–Araçuaí belt (c. 0.58 Ga); along the Araguaia and Paraguay belts (collision of Amazonia, c. 0.54–0.52 Ga); and the accretion of Cabo Frio terrane in the Ribeira Belt (c. 0.53–0.50 Ga).

Warm inflation as a way out of the swampland

Abstract: We discuss how dissipative effects and the presence of a thermal radiation bath, which are inherent characteristics of the warm inflation dynamics, can evade the recently proposed swampland conjectures. Different forms of dissipation terms, motivated by both microphysical quantum field theory and phenomenological models, are discussed and their viability to overcome the assumed swampland constraints is analyzed.

Study of tau-pair production in photon-photon collisions at LEP and limits on the anomalous electromagnetic moments of the tau lepton

Abstract: Tau-pair production in the process e(+)e(-) --> e(+)e(-) tau(+)tau(-) was studied using data collected by the DELPHI experiment at LEP2 during the years 1997 - 2000. The corresponding integrated luminosity is 650 pb(-1). The values of the cross-section obtained are found to be in agreement with QED predictions. Limits on the anomalous magnetic and electric dipole moments of the tau lepton are deduced.

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

Abstract: Objective To evaluate the efficacy and safety of sarilumab plus conventional synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with active moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response or intolerance to anti–tumor necrosis factor (anti-TNF) therapy. Methods Patients were randomly allocated to receive sarilumab 150 mg, sarilumab 200 mg, or placebo every 2 weeks for 24 weeks with background conventional synthetic DMARDs. The co-primary end points were the proportion of patients achieving a response according to the American College of Rheumatology 20% criteria for improvement (ACR20) at week 24, and change from baseline in the Health Assessment Questionnaire disability index (HAQ DI) at week 12. Each sarilumab dose was evaluated against placebo; differences between the 2 sarilumab doses were not assessed. Results The baseline characteristics of the treatment groups were similar. The ACR20 response rate at week 24 was significantly higher with sarilumab 150 mg and sarilumab 200 mg every 2 weeks compared with placebo (55.8%, 60.9%, and 33.7%, respectively; P < 0.0001). The mean change from baseline in the HAQ DI score at week 12 was significantly greater for sarilumab (least squares mean change: for 150 mg, −0.46 [P = 0.0007]; for 200 mg, −0.47 [P = 0.0004]) versus placebo (−0.26). Infections were the most frequently reported treatment-emergent adverse events. Serious infections occurred in 1.1%, 0.6%, and 1.1% of patients receiving placebo, sarilumab 150 mg, and sarilumab 200 mg, respectively. Laboratory abnormalities included decreased absolute neutrophil count and increased transaminase levels in both sarilumab groups compared with placebo. In this study, reductions in the absolute neutrophil count were not associated with an increased incidence of infections or serious infections. Conclusion Sarilumab 150 mg and sarilumab 200 mg every 2 weeks plus conventional synthetic DMARDs improved the signs and symptoms of RA and physical function in patients with an inadequate response or intolerance to anti-TNF agents. Safety data were consistent with interleukin-6 receptor blockade and the known safety profile of sarilumab.